Metrics to assess quality of life after management of early-stage lung cancer

Cancer Journal

Volumn 17, Issue 1, 2011, Pages 63-67

  Sloan, Jeff A ^a  

^a MAYO CLINIC   (United States)

Author keywords

clinical significance; Lung cancer; quality of life

Indexed keywords

ALGORITHM; CANCER PATIENT; CANCER SURVIVAL; EARLY CANCER; FEASIBILITY STUDY; HUMAN; LUNG CANCER; MEDICAL RESEARCH; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; QUESTIONNAIRE; REVIEW;

HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79551542374     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31820e15dc     Document Type: Review

References (58)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. 2010 CA Cancer J Clin. 2010;57:43-66.
2. Yang P, Allen MS, Aubry MC. Clinical features of 5, 628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452-462.
3. National Cancer Institute. SEER Cancer Statistics Review. 1975-2006. Washington, 2007.
4. Buchanan D, Milroy R, Baker L, et al. Perceptions of anxiety in lung cancer patients and their support network. Support Care Cancer. 2010;18:29-36.
5. Steinberg T, Roseman M, Kasymjanova G, et al. Prevalence of emotional distress in newly diagnosed lung cancer patients. Support Care Cancer. 2009;17:1493-1498.
6. Allen MS, Darling GE, Pechet TT, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81:1013-1019; discussion 1019-1020.
7. Kenny PM, King MT, Viney RC, et al. Quality of life and survival in the 2 years after surgery for non-small cell lung cancer. J Clin Oncol. 2008;26:233-241.
8. Bezjak A, Lee CW, Ding K, et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol. 2008;26:5052-5059.
9. Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of videoassisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol. 2009;27:2553-2562.
10. Cella D, Patel J. Improving health-related quality of life in non-small-cell lung cancer with current treatment options. Clin Lung Cancer. 2008;9:206-212.
11. Thompson E, Sola I, Subirana M. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer-a systematic review of the evidence. Lung Cancer. 2005;50:163-176.
12. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat. 2004;14:73-96.
13. Sloan JA. Applying QOL assessments: solutions for oncology clinical practice and research, part 1. Curr Probl Cancer. 2005;29:271-351;
14. Sloan JA. Applying QOL assessments: solutions for oncology clinical practice and research, part 2. Curr Probl Cancer. 2:2006; (30):235-331.
15. Fayers PM, Hopwood P, Harvey A, et al. Quality of life assessment in clinical trials - guidelines and a checklist for protocol writers: the UK Medical Research Council experience. MRC Cancer Trials Office. Eur J Cancer. 1997;33:20-28.
16. De Haes J, Curran D, Young T, et al. Quality of life evaluation in oncological clinical trials - the EORTC model. Eur J Cancer. 2000;36:821-825.
17. Bottomley A, Jones D, Claassens L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer. 2009;45:347-353.
18. Efficace F, Bottomley A, Osoba D, et al. Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision-making? J Clin Oncol. 2003;21:3502-3511.
19. Hahn EA, Cella D, Chassany O, et al. Precision of health-related qualityof-life data compared with other clinical measures. Mayo Clin Proc. 2007;82:1244-1254.
20. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1978;1:373-378.
21. Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42:55-64.
22. Bruner DW. Outcomes research in cancer symptom management trials: the Radiation Therapy Oncology Group (RTOG) conceptual model. J Natl Cancer Inst Monogr. 2007;37:12-15.
23. Siddiqui F, Kachnic LA, Movsas B. Quality-of-life outcomes in oncology. Hematol Oncol Clin North Am. 2006;20:165-185.
24. Smith DJ, Huntington J. Choosing the "correct" assessment tool. Curr Probl Cancer. 2006;30:272-282.
25. Qi Y, Schild SE, Mandrekar SJ, et al. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol. 2009;4:1075-1082.
26. Bottomley A, Efficace F, Thomas R, et al. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol. 2003;21:2982-2992.
27. Huschka M, Mandrekar SJ, Schaefer PL, et al. A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials. Cancer. 2007;109:787-795.
28. Basch E, Jia X, Heller G, et al. Adverse symptom reporting by patients versus clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1-9.
29. Basch E. Patient-reported outcomes in drug safety evaluation. Ann Oncol. 2009;20:1905-1906.
30. Guyatt GH, Osoba D, Wu A, et aland the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371-383.
31. Revicki DA, Erickson PA, Sloan JA, et al. Interpreting and reporting results based on patient-reported outcomes. Value Health. 2007;10(suppl 2):S116-S124.
32. Sloan JA, Frost MH, Berzon R, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006;14:988-998.
33. Sloan J, Symonds T, Vargas-Chanes D, et al. Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J. 2003;37:23-31.
34. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
35. Sloan JA. The FDA Guidance for patient-reported outcomes: what does it mean and how will it impact clinical trials?. Value Health. 2007;10(suppl 2):S146.
36. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol. 2005;58:1217-1219.
37. Sloan JA. Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. Copd. 2005;2:57-62.
38. Butt Z, Wagner LI, Beaumont JL, et al. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage. 2008;35:20-30.
39. Degner L, Sloan J. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer patients. J Pain Symptom Manage. 1995;10:423-431.
40. Gotay CC, Kawamoto CT, Bottomley A, et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355-1363.
41. Montezari A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102.
42. Movsas B, Moughan J, Sarna L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced nonsmall-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009;27:5816-5822.
43. Higginson IJ, Carr AJ. Measuring quality of life: using quality of life measures in the clinical setting. BMJ. 2001;322:1297-1300.
44. Chang C-H, Cella D, Masters GA, et al. Real-time clinical application of quality of life assessment in Lung Cancer. Clin Lung Cancer. 2002;4:104-109.
45. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-oflife assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288:3027-3034.
46. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient wellbeing: a randomized controlled trial. J Clin Oncol. 2004;22:714-724.
47. Taenzer P, Bultz BD, Carlson LE, et al. Impact of computerized quality of life screening on physician behavior and patient satisfaction in lung cancer outpatients. Psychooncology. 2000;9:203-213.
48. Buchanan DR, O'Mara A, Kelaghan JW, et al. Challenges and recommendations for advancing the state-of-the-science of quality-of-life assessment in symptom management trials. Cancer. 2007;110:1621-1628.
49. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer. 1994;30 A: 635-642.
50. Butt Z, Webster K, Eisenstein A, et al. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy Lung Scale. Hematol Oncol Clin North Amer. 2005;19:389-420.
51. Gralla RJ, Edelman MJ, Detterbeck FC, et al. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Support Care Cancer. 2009;17:307-314.
52. Sloan JA, Berk L, Roscoe J, et al. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials network. J Clin Oncol. 2007;25:5070-5077.
53. Ware JE, Kosinski M. SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1. 2nd ed. Lincoln, RI: Quality-Metric Incorporated; 2001.
54. Locke DE, Decker PA, Sloan JA, et al. Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients [published online ahead of print August 20, 2007]. J Pain Symptom Manage. 2007;34:628-638.
55. Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol. 1996;23:31-40.
56. Sloan JA, Zhao CX. Genetics and quality of life. Curr Probl Cancer. 2006;30:255-260.
57. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients. The M. D. Anderson Symptom Inventory. Cancer. 2000;89:1634-1646.
58. Hobday TJ, Kugler JW, Mahoney MR, et al. Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol. 2002;20:4574-4580.